SME Instrument Phase I winner project


Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment

The Infarnosys project aims to launch a novel, combined biomarker diagnostic system on the market that will help clinicians and laboratories to earlier and better diagnose cardiac ischemia/reperfusion injury and prognosticate the effectiveness of the treatment. The innovative process measures MMP-2, MMP-9 and nitrotyrosine levels and tests MMP inhibitors in artery blood samples. Measuring MMP and nitrotyrosine levels enables predicting the occurrence of heart attack and helps to start the treatment much earlier.

For both men and women, coronary artery disease is the leading cause of death in Europe in spite of the fact that 80% of premature heart diseases are preventable. Earlier and better diagnosis of cardiac ischemia and reperfusion injury is crucial for reducing the number of deaths connected to cardiovascular diseases.

Our diagnostic marker combination has been tested already in several pre-clinical studies and in a pilot clinical study (Bencsik et al, Eur J Clin Invest, 2015).

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 698297.